drugset / Trial / NCT06681337
Universal CAR-T Cell Therapy for Refractory Lupus Nephritis
Phase 0
Not yet recruiting
10 enrolled
Bioray Laboratories
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collab
NaSingle-groupOpen-labelTreatment
Summary
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
Timeline
- Start
- 2024-11-25
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | — | — |
| Subject | CD19 CAR-T | Cell therapy | — | — |